An herbal drug, developed jointly by the National Botanical Research Institute (NBRI) and the Central Institute of Medicinal and Aromatic Plants (CIMAP), branded as BGR-34, has been commercialized by Delhi-based Aimil Pharmaceuticals and marketed as a potentially side-effect free treatment for diabetes. However, a search for publications outlining trials conducted to support the claimed "67% … Continue reading BGR-34 for Diabetes: Where is the evidence?